Medpace Holdings Inc (MEDP) - Total Assets
Based on the latest financial reports, Medpace Holdings Inc (MEDP) holds total assets worth $2.06 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Medpace Holdings Inc - Total Assets Trend (2014–2025)
This chart illustrates how Medpace Holdings Inc's total assets have evolved over time, based on quarterly financial data. Also see Medpace Holdings Inc market capitalisation for the company's overall valuation and market capitalisation.
Medpace Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Medpace Holdings Inc's total assets of $2.06 Billion consist of 50.1% current assets and 49.9% non-current assets. Review MEDP total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.2% |
| Accounts Receivable | $402.08 Million | 20.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $33.42 Million | 1.7% |
| Goodwill | $662.40 Million | 33.5% |
Asset Composition Trend (2014–2025)
This chart illustrates how Medpace Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See MEDP live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medpace Holdings Inc's current assets represent 50.1% of total assets in 2025, an increase from 12.2% in 2014.
- Cash Position: Cash and equivalents constituted 25.2% of total assets in 2025, up from 5.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, a decrease from 83.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 33.5% of total assets.
Medpace Holdings Inc Competitors by Total Assets
Key competitors of Medpace Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468
|
China | CN¥1.76 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
IZOTROPIC CORP.
F:1R3
|
Germany | €439.78K |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
Medpace Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.73 | 0.43 | 1.24 |
| Quick Ratio | 0.73 | 0.43 | 1.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-385.14 Million | $-699.64 Million | $124.04 Million |
Medpace Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Medpace Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 38.07 |
| Latest Market Cap to Assets Ratio | 8.28 |
| Asset Growth Rate (YoY) | -6.0% |
| Total Assets | $1.98 Billion |
| Market Capitalization | $16.36 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Medpace Holdings Inc's assets at a significant premium (8.28x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Medpace Holdings Inc's assets decreased by 6.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Medpace Holdings Inc (2014–2025)
The table below shows the annual total assets of Medpace Holdings Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.98 Billion | -5.97% |
| 2024-12-31 | $2.10 Billion | +26.80% |
| 2023-12-31 | $1.66 Billion | +22.50% |
| 2022-12-31 | $1.35 Billion | -18.52% |
| 2021-12-31 | $1.66 Billion | +19.36% |
| 2020-12-31 | $1.39 Billion | +21.66% |
| 2019-12-31 | $1.14 Billion | +18.09% |
| 2018-12-31 | $967.93 Million | +1.81% |
| 2017-12-31 | $950.72 Million | -2.90% |
| 2016-12-31 | $979.11 Million | -0.50% |
| 2015-12-31 | $984.04 Million | -10.29% |
| 2014-12-31 | $1.10 Billion | -- |
About Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medica… Read more